Our Philosophy to Partnering
Mirati is seeking collaboration opportunities for novel approaches to oncology with assets that target kinase inhibitors and epigenetic targets.
Currently, worldwide rights to all pipeline programs are owned by Mirati Therapeutics except certain Asian rights for sitravatinib, where the program is partnered with BeiGene.
Collaboration Inquiries
Jessica M. Corson, MBA
Email: bd@Mirati.com
Phone: 858-332-3410